21575-13-3

Basic information

• Product Name: 4-Amino-6,7-dimethoxyquinazoline
• Synonyms: 4-AMINO-6,7-DIMETHOXYQUINAZOLINE;6,7-Dimethoxy-4-Amino-Quinzaoline;6,7-DiMethoxy-4-quinazolinaMine;6,7-diMethoxyquinazolin-4-aMine;6,7-Dimethoxy-quinazolin-4-ylamine
• CAS NO: 21575-13-3
• Molecular Formula: C₁₀H₁₁N₃O₂
• Molecular Weight: 205.21
• EINECS: 1533716-785-6
• Product Categories: Tinibs
• Mol File: 21575-13-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 383.053 °C at 760 mmHg
• Flash Point: 185.464 °C
• Appearance: /
• Density: 1.28 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.642
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-Amino-6,7-dimethoxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-6,7-dimethoxyquinazoline(21575-13-3)
• EPA Substance Registry System: 4-Amino-6,7-dimethoxyquinazoline(21575-13-3)

Safety Data

• Hazardous Substances Data: 21575-13-3(Hazardous Substances Data)

Usage

General Description

4-Amino-6,7-dimethoxyquinazoline is a chemical compound with the molecular formula C11H12N2O2. It is classified as a quinazoline derivative and is commonly used in the field of medicinal chemistry for the synthesis of pharmaceutical drugs. 4-Amino-6,7-dimethoxyquinazoline has been studied for its potential biological activities, including its role as an anti-cancer agent. It has also been investigated for its anti-inflammatory and anti-fibrotic properties. Additionally, 4-Amino-6,7-dimethoxyquinazoline has been researched for its potential use in the treatment of neurodegenerative diseases. Its unique chemical structure and diverse potential applications make it an important target for further research and development in the pharmaceutical industry.

InChI:InChI=1/C10H11N3O2/c1-14-8-3-6-7(4-9(8)15-2)12-5-13-10(6)11/h3-5H,1-2H3,(H2,11,12,13)

Upstream product

• 26961-27-3 2-amino-4,5-dimethoxybenzonitrile 
• 77287-34-4 formamide 
• 3473-63-0 formamidine acetic acid 
• 13790-39-1 6,7-dimethoxy-4-chloroquinazoline 
• 109305-98-8 2-bromo-4,5-dimethoxybenzonitrile 
• 6313-33-3 formamidine hydrochloride 

Downstream Products

• 1352198-29-8 N-[4,5-dimethoxy-2-([1,2,4]oxadiazol-5-yl)phenyl]formamide oxime 
• 1352198-55-0 N-[4,5-dimethoxy-2-(3-methyl[1,2,4]oxadiazol-5-yl)phenyl]formamide oxime 
• 1418025-25-8 7-chloro-3-[(6,7-dimethoxy-quinazolin-4-ylamino)methyl]-1-phenyl-1H-quinolin-4-one 

Relevant articles and documents

Synthetic method of erlotinib intermediate

The invention relates to a synthesis method of an erlotinib intermediate, which comprises the following steps: reacting 2-bromo-4,5-dimethoxybenzonitrile with formamidine hydrochloride under the actions of alkali and a catalyst to generate a compound 3; reacting with 1-bromo-triethynylbenzene under the catalysis of alkali to generate a compound 2; carrying out a reaction on the compound 2 with 48%hydrobromic acid under the action of a catalyst to obtain a compound 1. The method is mild in condition, simple in step, safe, environmentally friendly and suitable for industrial production.

Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)-phenyl)-3-(2-(amino)pyridin-3-yl)ureas as Novel KDR Kinase Inhibitors

Kinase insert Domain-containing Receptor (KDR) is one of the currently validated targets for anticancer drug discovery and development. Herein, a series of o-amino-arylurea derivatives have been synthesized and evaluated for their kinase inhibitory activity. The optimization on the basis of biological screening and molecular modeling resulted in obvious increase in KDR kinase inhibitory activity compared with the hit compound. Eventually, we identified a potent inhibitor 5a of 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-((quinolin-4-ylmethyl) amino)pyridin-3-yl)urea scaffold against KDR (IC50 = 0.0689 μM), which can serve as good starting point for further KDR inhibitor optimization and development.

Polycyclic N-heterocyclic compounds, part 67: Reaction of 6,7-substituted N-(quinazolin-4-yl)amidine derivatives with hydroxylamine hydrochloride: Formation of in vitro inhibitors of pentosidine

Reactions of N-(quinazolin-4-yl)amidines and their amide oximes with hydroxylamine hydrochloride gave cyclization products that were formed by an initial ring cleavage of the pyrimidine component followed by a ring closure formation of 1,2,4-oxadiazole to